This report gives an insight into the global biosimilars market and predicts the future growth prospects and the trends that may exhibit in the market during the period of 2022-2029. The future growth has been calculated by taking into account the present growth rate and the overall market size. We have also discussed the alternatives that pose a threat to the growth of the market. In, this report we have categorized global biosimilars market into segments that are: By Molecule (Infliximab, Insulin Glargine, Epoetin Alfa, Etanercept, Filgrastim, Somatropin, Rituximab, Follitropin Alfa, Adalimumab, Pegfilgrastim, Trastuzumab, Bevacizumab, Others); By Manufacturing (In-house Manufacturing, Contract Manufacturing); By Indication (Auto-Immune Disease, Blood Disorder, Diabetes, Oncology, Growth Deficiency, Female Infertility, Others); By Region (North America, Asia Pacific, Europe, Latin America, Middle East and Africa)
We have also illustrated the vendor landscape and conducted a detailed analysis of the top five global vendors of the global biosimilars market. The report also presents an analysis of the drivers that enable the growth of the market, the key challenges faced by the vendors and the market as a whole, and the upcoming trends that can have an impact on the market.
Marketlook Consulting has collected key data related to the global biosimilars market and analyzed these data using a variety of methods. The market dynamics have been ascertained following a detailed study of the micro, meso and microeconomic indicators in the market. The report is based on in-depth qualitative and quantitative analyses of the global sports medicine market. The qualitative analysis involved the application of various projection and sampling techniques. The qualitative analysis involved primary interviews, surveys and vendor briefings. The data gathered as a result of these processes were validated through experts' opinions.
Global Biosimilars Market Would Cross USD 42.4 Bn By 2029
Global biosimilars market report provides comprehensive qualitative and quantitative insights on the industry potential, key factors impacting sales and purchase decisions, hotspots, and opportunities available for biosimilars solution providers across the Globe. This report on the global biosimilars market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2029. The report provides revenue of global biosimilars for the period 2019-2029, considering 2021 as the base year and 2022-29 as the forecast year. The report also provides the compound annual growth rate (CAGR 21%) of global biosimilars from 2022 to 2029.
Segmental Analysis of the global biosimilars market Study
The global biosimilars market study is segmented based on the various parameters by identifying their business activities, geographical presence, key application areas, end-users, etc., The report covers the market share analysis of all the segments from year 2022-2029. From a strategic point of view, the market outlook covers several frameworks including SWOT Analysis, Value Chain Analysis, and Porter's Five Forces Analysis while also offering an evaluation of the Product/Market Lifecycle.
Geographical Coverage of the global biosimilars market Study
For a better understanding of the global biosimilars, the market is segmented into geographies such as the North America (U.S, Canada), Europe (U.K, France, Germany, Russia, Italy, Rest of Europe), Asia Pacific (China, Japan, India, Australia, South-Korea, Rest of APAC), Latin America (Brazil, Mexico, Rest of Latin America), Middle East and Africa (Saudi Arabia, The U.A.E, South Africa, Rest of MEA). The country level analysis in each region is also provided in a very exhaustive manner.
Company Analysis on the global biosimilars market Study
In the report, the degree of competition among prominent global companies has been elaborated by analyzing several leading key players operating worldwide. The specialist team of research analysis sheds light on various traits such as global market competition, market share, most recent industry advancements, innovative product launches, partnerships, mergers and acquisition by leading companies in the market. The major players have been analyzed by using research methodologies for getting insight on global competition.
Table of Content:
1. Introduction
1.1. Research Objective
1.2. Research Methodology
1.3. Research Process
1.4. Respondent Profile
2. Executive Summary
3. Global Biosimilars Market Outlook, 2019-2029F
3.1. Market Size & Analysis
3.2. Market Share & Analysis
3.2.1. By Molecule
3.2.1.1. Infliximab
3.2.1.2. Insulin Glargine
3.2.1.3. Epoetin Alfa
3.2.1.4. Etanercept
3.2.1.5. Filgrastim
3.2.1.6. Somatropin
3.2.1.7. Rituximab
3.2.1.8. Follitropin Alfa
3.2.1.9. Adalimumab
3.2.1.10 Pegfilgrastim
3.2.1.11 Trastuzumab
3.2.1.12 Bevacizumab
3.2.1.13 Others
3.2.2. By Indication
3.2.2.1. Auto-Immune Disease
3.2.2.2. Blood Disorder
3.2.2.3. Diabetes
3.2.2.4. Oncology
3.2.2.5. Growth Deficiency
3.2.2.6. Female Infertility
3.2.2.7. Others
3.2.3. By Manufacturing
3.2.3.1. In-house Manufacturing
3.2.3.2. Contract Manufacturing
3.2.4. By Region
3.2.4.1. Asia-Pacific
3.2.4.2. Europe
3.2.4.3. North America
3.2.4.4. Middle East & Africa
3.2.4.5. Latin America
4. Asia-Pacific Biosimilars Market Outlook, 2019-2029F
4.1. Market Size & Analysis
4.2. Market Share & Analysis
4.2.1. By Molecule
4.2.2. By Indication
4.2.3. By Manufacturing
4.2.4. By Country
4.2.4.1. China
4.2.4.2. India
4.2.4.3. Japan
4.2.4.4. South Korea
4.2.4.5. Australia
4.2.4.6. Rest of Asia-Pacific
5. Europe Biosimilars Market Outlook, 2019-2029F
5.1. Market Size & Analysis
5.2. Market Share & Analysis
5.2.1. By Molecule
5.2.2. By Indication
5.2.3. By Manufacturing
5.2.4. By Country
5.2.4.1. United Kingdom
5.2.4.2. Germany
5.2.4.3. France
5.2.4.4. Italy
5.2.4.5. Russia
5.2.4.6. Rest of Europe
6. North America Biosimilars Market Outlook, 2019-2029F
6.1. Market Size & Analysis
6.2. Market Share & Analysis
6.2.1. By Molecule
6.2.2. By Indication
6.2.3. By Manufacturing
6.2.4. By Country
6.2.4.1. United States
6.2.4.2. Canada
7. Latin America Biosimilars Market Outlook, 2019-2029F
7.1. Market Size & Analysis
7.2. Market Share & Analysis
7.2.1. By Molecule
7.2.2. By Indication
7.2.3. By Manufacturing
7.2.4. By Company
7.2.4.1. Brazil
7.2.4.2. Mexico
7.2.4.3. Rest of Latin America
8. Middle East & Africa Biosimilars Market Outlook, 2019-2029F
8.1. Market Size & Analysis
8.2. Market Share & Analysis
8.2.1. By Molecule
8.2.2. By Indication
8.2.3. By Manufacturing
8.2.4. By Company
8.2.4.1. Saudi Arabia
8.2.4.2. UAE
8.2.4.3. South Africa
8.2.4.4. Rest of Middle East and Africa
9. Global Biosimilars Market Dynamics
9.1. Growth Drivers
9.2. Challenges
9.3. Impact Analysis
10. Global Biosimilars Market Opportunities
11. Global Biosimilars Value Chain Analysis
12. Global Biosimilars Market Policies and Regulations
13. Global Biosimilars Market Trends & Insights
15. Global Biosimilars Market Porter's Five Forces Analysis
15. Global Biosimilars Market-Entropy
15.1. New Product Launches
15.2. M&A, Collaborations, JVs, and Partnerships
16. Global Biosimilars Market Company Analysis
16.1. Novartis AG
16.2. Pfizer Inc.
16.3. Amgen Inc.
16.5. Coherus Biosciences Inc.
16.5. Mylan NV (Viatris Inc.)
16.6. Samsung Bioepis Co. Ltd
16.7. Pfizer Inc.
16.8. Eli Lilly & Company
16.9. Dr. Reddy's Laboratories
16.10. Biocad
17. About Us & Contact Details
The Biologics and Biosimilars CXO Services Market is set to witness immense growth during the forecast period 2024-2031. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive landsca...
Executive Summary
Azoth Analytics has released a research report titled Global Therapeutics Market (2024 Edition) which provides a complete analysis of the Global Therapeutics industry in terms of market segmentation By Molecule Type (Biologics and Biosimilars, Small Molecules), By Th...
Asia Pacific bioprocess technology market will grow by 15.0% annually with a total addressable market cap of $170.71 billion over 2024-2033. The growth is driven an increasing prevalence of chronic diseases, the widespread use of bioprocess technology, rising expenditures on R&D in the biotechnology...
Europe bioprocess technology market was valued at $6.56 billion in 2023 and will grow by 13.7% annually over 2023-2033. The growth is driven an increasing prevalence of chronic diseases, the widespread use of bioprocess technology, rising expenditures on R&D in the biotechnology sector, ongoing tech...
North America bioprocess technology market is projected to grow by 13.3% annually in the forecast period and reach $29.68 billion by 2033. The growth is driven an increasing prevalence of chronic diseases, the widespread use of bioprocess technology, rising expenditures on R&D in the biotechnology s...
Global bioprocess technology market will reach $88.39 billion by 2033, growing by 13.8% annually over 2023-2033. The growth is driven an increasing prevalence of chronic diseases, the widespread use of bioprocess technology, rising expenditures on R&D in the biotechnology sector, ongoing technologic...
Asia Pacific biopharmaceuticals market will grow by 10.3% annually with a total addressable market cap of $1,776.7 billion over 2024-2033, driven by the prevalence of chronic diseases along with aging population, rising investments in novel biopharma drugs, technological advancement for drug discove...
Europe biopharmaceuticals market was valued at $116.5 billion in 2023 and will grow by 8.6% annually over 2023-2033, driven by the prevalence of chronic diseases along with aging population, rising investments in novel biopharma drugs, technological advancement for drug discovery, growing clinical t...
North America biopharmaceuticals market is projected to grow by 8.4% annually in the forecast period and reach $407.2 billion by 2033, driven by the prevalence of chronic diseases along with aging population, rising investments in novel biopharma drugs, technological advancement for drug discovery, ...
Global biopharmaceuticals market will reach $1,001.1 billion by 2033, growing by 8.8% annually over 2023-2033. The growth is driven by the prevalence of chronic diseases along with aging population, rising investments in novel biopharma drugs, technological advancement for drug discovery, growing cl...